BridgeMD
New treatment option for Myeloma
Official title Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
ClinicalTrials.gov ID: NCT07202078
What this study is testing
What is Trimethoprim / Sulfamethoxazole?
Trimethoprim / Sulfamethoxazole is an investigational medicine, given as an once-daily, being studied as a potential treatment for myeloma.
Also referred to as Co-Trimoxazole.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers. The best way to find out this information is to directly compare the effect of different treatment strategies in patients with blood cancers.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- None.
You likely can't join if
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal...
- Received immunoglobulin replacement in the preceding three months.
- Objection to receiving immunoglobulin products.
- Known history of IgA deficiency with anti-IgA.
- History of severe allergy to immunoglobulin products.
See the full eligibility criteria
- None.
- Prior or planned allogeneic haematopoietic stem cell transplantation.
- Already receiving systemic antibiotic prophylaxis for the purpose of preventing bacterial infection (NB: patients may receive antiviral, antifungal and PJP prophylaxis).
- Received immunoglobulin replacement in the preceding three months.
- Objection to receiving immunoglobulin products.
- Known history of IgA deficiency with anti-IgA.
- History of severe allergy to immunoglobulin products.
- Current active infection requiring systemic antibiotics.
- Allergy or intolerance of all domain antibiotic options.
- Pregnant or breastfeeding.
- Severe renal impairment (estimated or measured creatinine clearance of \< 30 mL/min).
- Previous splenectomy.
- Previous participation in this domain.
- Treating team deems enrolment in the domain is not in the best interest of the patient.
The study team makes the final eligibility decision.
Where it's taking place
- Adelaide, South Australia, Australia
- Melbourne, Victoria, Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Adelaide, South Australia, Australia; Melbourne, Victoria, Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.